Kiniksa Pharmaceuticals to Report Fourth Quarter and Full Year 2025 Financial Results on February 24, 2026
Kiniksa Pharmaceuticals (Nasdaq: KNSA) will report its fourth quarter and full year 2025 financial results on Tuesday, February 24, 2026.
Rhea-AI Summary
Kiniksa Pharmaceuticals (Nasdaq: KNSA) will report its fourth quarter and full year 2025 financial results on Tuesday, February 24, 2026.
The company will host a conference call and live webcast at 8:30 a.m. ET. A live webcast will be available via the Investors & Media section of the company's website, and a replay will be posted approximately 48 hours after the event. Telephone participants must register to receive dial-in details and a unique passcode.
Positive
- None.
Negative
- None.
Details
News Market Reaction – KNSA
In the Feb 20 session, KNSA gained 1.27%, reflecting a mild positive market reaction.
Data tracked by StockTitan Argus on the day of publication.
Key Figures
- Earnings call date
- February 24, 2026
- Scheduled fourth quarter and full year 2025 results call
- Earnings call time
- 8:30 a.m. Eastern Time
- Start time for Q4 and full year 2025 results call
- Replay availability
- Approximately 48 hours
- Delay before webcast replay posted on company website
- Current share price
- $45.39
- Price before earnings date announcement on 2026-02-19
- 52-week range
- $18.255–$47.26
- Shares trading 148.64% above low and 3.96% below high
- Market capitalization
- $3,440,369,501
- Equity value before the earnings date announcement
Historical Context
-
Unaudited 2025 ARCALYST revenue, 62% growth and higher 2026 guidance.
-
Planned presentation at J.P. Morgan Healthcare Conference with webcast access.
-
Jefferies Global Healthcare Conference presentation and webcast logistics.
-
Q3 2025 beat with 61% ARCALYST growth, raised 2025 guidance and positive net income.
-
Announcement of Q3 2025 results date and webcast details.
24h Move is the share-price change in the day after each event; other market factors may also have contributed.
AI-generated analysis. How Rhea-AI works. Not financial advice.
LONDON, Feb. 19, 2026 (GLOBE NEWSWIRE) -- Kiniksa Pharmaceuticals International, plc (Nasdaq: KNSA) announced today that it will host a conference call and live webcast on Tuesday, February 24, 2026 at 8:30 a.m. Eastern Time to report its fourth quarter and full year 2025 financial results and recent portfolio execution.
A live webcast will be accessible through the Investors & Media section of the company’s website at www.kiniksa.com. Individuals interested in participating in the call via telephone may register here. Upon registration, all telephone participants will receive a confirmation email detailing how to join the conference call, including the dial-in number along with a unique passcode and registrant ID that can be used to access the call. A replay of the event will also be available on Kiniksa’s website within approximately 48 hours after the event.
About Kiniksa
Kiniksa is a biopharmaceutical company dedicated to improving the lives of patients suffering from debilitating diseases by discovering, acquiring, developing, and commercializing novel therapies for diseases with unmet need, with a focus on cardiovascular indications. Kiniksa’s portfolio of assets is based on strong biologic rationale or validated mechanisms and offers the potential for differentiation. For more information, please visit www.kiniksa.com.
Every Second Counts! ®
Kiniksa Investor & Media Contact
Jonathan Kirshenbaum
(781) 829-3949
jkirshenbaum@kiniksa.com
FAQ
AI-generated questions and answers. How Rhea-AI works. Not financial advice.